Neogen Chemicals Q1 FY27 Results: Revenue Grows 34%, PAT Jumps 67%; Board Approves ₹600 Crore QIP

What Happened ?

key details

Strong Operating Performance:

• Revenue growth was driven by higher volumes across major product categories.
• Organolithium business achieved its highest-ever quarterly revenue.
• Neogen Ionics generated ₹19 crore of revenue versus ₹5 crore a year ago.
• Cost pass-through mechanisms helped protect operating margins despite higher freight, packaging and utility costs. 

Dahej Plant Update:

• Reconstruction of the Dahej manufacturing facility has been completed.
• Trial runs are currently underway.
• Commercial production is expected to begin shortly.
• Insurance recoveries have reached ₹164 crore, including ₹155 crore received through insurance claims and ₹9 crore from salvage.
• Net insurance claim receivable currently stands at ₹186 crore on a consolidated basis. 

Battery Chemicals Expansion:

The company continued expanding its battery materials business through Neogen Ionics.

Key developments include:

• Electrolyte project remains on schedule.
• Electrolyte salts project targeted for commissioning during H2 FY27.
• Mechanical assembly completed for electrolyte facilities with trial production underway.
• Four major international customers have provided provisional approvals for Lithium Electrolyte Salts.
• Final site audits completed for three US-based electrolyte manufacturers.
• Commercial supplies will begin after final plant approvals.

Major CAPEX Progress:

• Total Battery Materials project cost: ₹1,795 crore
• Cumulative CAPEX incurred: ₹1,298 crore
• Q1 FY27 CAPEX: ₹218 crore
• Dahej Phase 1 target completion: February 2027
• Pakhajan Phase 2 target completion: March 2027

Fund Raising:

• The Board approved raising up to ₹600 crore through a Qualified Institutional Placement (QIP), subject to shareholder and regulatory approvals. The proceeds are expected to support future expansion and growth initiatives.

Risk Analysis

Summary:

• Although operating performance remained strong, higher finance costs, ongoing expansion spending and dependence on successful commissioning of new battery material facilities remain important factors to monitor.

Key Risks:

• Interest costs increased 64% YoY due to higher debt for CAPEX.
• Working capital requirements increased because of geopolitical supply chain inflation.
• Delay in insurance claim receipts impacted profitability.
• Battery materials business depends on successful commercial approvals and timely commissioning.
• Forward-looking guidance remains subject to market, regulatory and execution risks. 

Worst Case:

• Any delay in commissioning the Dahej plant, obtaining customer approvals for battery chemicals, or executing expansion projects could postpone revenue growth and affect margin improvement.

Risk Level: Medium

Company Commentary

Managing Director Dr. Harin Kanani said the company delivered a strong start to FY27 driven by robust volume growth, record Organolithium revenues and significant progress in the battery chemicals business.

Management stated that:

• The replacement Dahej plant is nearing commercial operations.
• Battery materials projects remain on schedule.
• Customer validations and international approvals continue to progress.
• FY27 will be a defining execution year as Neogen scales its battery materials platform and resumes normalized growth from the rebuilt Dahej facility.
• The company reaffirmed its previously shared guidance and remains focused on executing its strategic CAPEX roadmap while creating long-term shareholder value.